Mainz Biomed B.V. (MYNZ): Price and Financial Metrics
MYNZ Price/Volume Stats
| Current price | $0.91 | 52-week high | $6.00 |
| Prev. close | $0.90 | 52-week low | $0.85 |
| Day low | $0.88 | Volume | 62,500 |
| Day high | $0.95 | Avg. volume | 82,691 |
| 50-day MA | $1.00 | Dividend yield | N/A |
| 200-day MA | $2.07 | Market Cap | 10.87M |
MYNZ Stock Price Chart Interactive Chart >
Mainz Biomed B.V. (MYNZ) Company Bio
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic tests for clinical diagnostics in the area of human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, an early-stage molecular lateral-flow test; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Latest MYNZ News From Around the Web
Below are the latest news stories about MAINZ BIOMED NV that investors may wish to consider to help them evaluate MYNZ as an investment opportunity.
Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for EmployeesHermann Bantleon GmbH (“Bantleon), Shareholder of German AVIA, will Offer the ColoAlert® At-Home Screening Test to Employees Across All Three of Their German Locations, Namely Ulm, Ulm-Nord, and Crimmitschau, in Q1 2024BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the second phase of its colorectal cance |
Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in PolandBERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its active participation alongside Polish partner TestDNA at two significant gastroenterology conferences in Poland, strengthening their commitment to advancing colorectal cancer (CRC) detection and gastroenterological innovation. The first attended conferenc |
While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal CancerObesity has been linked to development of a range of diseases and unfortunately, cancer. More specifically, the National Cancer Institute estimated that colorectal cancer is 1.3 times more likely in obese individuals. Therefore, this is a highly lucrative segment for pharmaceutical companies. Yet, the big pharma giant, Pfizer Inc (NYSE: PFE) abandoned its obesity drug that failed during the phase 2 trial due to exhibited side-effects. But a clinical-stage company, Altimmune Inc (NASDAQ: ALT), an |
Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA BiomarkersGroundbreaking Results Demonstrate Sensitivity for Colorectal Cancer of 97% with Specificity of 97% and Advanced Adenoma Sensitivity of 82%Results Exceed those from the Company’s European ColoFuture Clinical Study of the Same DesignColoFuture and eAArly DETECT Studies Support Inclusion of a Portfolio of Novel mRNA Biomarkers in Pivotal FDA PMA Clinical Trial (ReconAAsense); Trial is On Track to Commence Enrollment in Mid-2024 BERKELEY, Calif. and MAINZ, Germany, Dec. 05, 2023 (GLOBE NEWSWIRE) -- |
Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via WebcastBERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces that its presentation at the 35th Annual Piper Sandler Healthcare Conference, to be delivered by Chief Executive Officer, Guido Baechler and Bill Caragol, Chief Financial Officer, will be available to view live and post event via webcast by registering at the follo |
MYNZ Price Returns
| 1-mo | -12.98% |
| 3-mo | -15.74% |
| 6-mo | -60.43% |
| 1-year | -79.50% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -21.55% |
| 2023 | -83.66% |
| 2022 | -31.67% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...